Enzon Pharma has posted a net loss of $8.35m for the third quarter 2010, compared to net income of $133,000 for the comparable period in 2009.
The company’s operating loss was $7.39m, for the three months ended 30 September 2010, compared to operating loss of $10.55m for the comparable period in 2009.
Enzon Pharma Board chairman Alex Denner said that their focus on their pipeline of oncology programs is translating into encouraging results as they advance their clinical programs and continue to share new preclinical data demonstrating the potential of their pipeline.
"In addition, we continue to realise the operating efficiencies associated with the strategic restructuring initiatives enacted at the beginning of the year, which established an operating structure appropriately aligned with our development activities," Denner said.